tbuckley/cabot-search huggingface dataset:
Novel Techniques for the Diagnosis of Acute Myocarditis: A Clinical Cardiovascular Magnetic Resonance Study
Authors: V M Ferreira, S K Piechnik, E Dall'Armellina, T D Karamitsos, J M Francis, N Ntusi, C Holloway, R P Choudhury, A Kardos, Robson, M G Friedrich, S Neubauer
Journal: Circulation (2012)
Pathology of Rat Hepatoma 31
Authors: Julius White, Albert J. Dalton, Jesse E. Edwards
Journal: JNCI Journal of the National Cancer Institute (1942)

Pathology of Rat Hepatoma 31 Get access Julius White, Julius White senior biochemist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar Albert J. Dalton, Albert J. Dalton cytologist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar Jesse E. Edwards Jesse E. Edwards research fellow National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 2, Issue 6, June 1942, Pages 539–554, https://doi.org/10.1093/jnci/2.6.539 Published: 01 June 1942
GW28-e0582 Activin receptor-like kinase 4 deficiency attenuates atrial remodeling and vulnerability to atrial fibrillation induced by pressure overload in mice
Authors: Qian Wang, Ying Yu, Yihe Chen, Li Changyi, Jianwen Hou, Xiaomeng Chen, Yudong Fei, Yigang Li
Journal: Journal of the American College of Cardiology (2017)
Neoadjuvant eribulin following anthracycline and taxane in triple negative breast cancer (HOPE): A multicenter, two stage, phase II trial
Authors: S. Di Cosimo, N. Laverde, M.E. Cazzaniga, D. Generali, G.V. Bianchi, E. Tagliabue, V. Torri, F. Crippa, B. Paolini, G. Scaperrotta, A. Gulino, C. Tripodo, M.P. Colombo, S. Folli, F.G. de Braud
Journal: Annals of Oncology (2017)
An analysis of IL-36 signature genes and individuals with <i>IL1RL2</i> knockout mutations validates IL-36 as a psoriasis therapeutic target
Authors: Satveer K. Mahil, Marika Catapano, Paola Di Meglio, Nick Dand, Helena Ahlfors, Ian M. Carr, Catherine H. Smith, Richard C. Trembath, Mark Peakman, John Wright, Francesca D. Ciccarelli, Jonathan N. Barker, Francesca Capon
Journal: Science Translational Medicine (2017)

Interleukin (IL)-36α, IL-36β, and IL-36γ are innate mediators of acute epithelial inflammation. We sought to demonstrate that these cytokines are also required for the pathogenesis of plaque psoriasis, a common and chronic skin disorder, caused by abnormal T helper 17 (TH17) cell activation. To investigate this possibility, we first defined the genes that are induced by IL-36 cytokines in primary human keratinocytes. This enabled us to demonstrate a significant IL-36 signature among the transcripts that are up-regulated in plaque psoriasis and the susceptibility loci associated with the disease in genome-wide studies. Next, we investigated the impact of in vivo and ex vivo IL-36 receptor blockade using a neutralizing antibody or a recombinant antagonist. Both inhibitors had marked anti-inflammatory effects on psoriatic skin, demonstrated by statistically significant reductions in IL-17 expression, keratinocyte activation, and leukocyte infiltration. Finally, we explored the potential safety profile associated with IL-36 blockade by phenotyping 12 individuals carrying knockout mutations of the IL-36 receptor gene. We found that normal immune function was broadly preserved in these individuals, suggesting that IL-36 signaling inhibition would not substantially compromise host defenses. These observations, which integrate the results of transcriptomics and model system analysis, pave the way for early-stage clinical trials of IL-36 antagonists.
Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK)
Authors: D.R. Gandara, M. Kowanetz, T.S.K. Mok, A. Rittmeyer, L. Fehrenbacher, D. Fabrizio, G. Otto, C. Malboeuf, D. Lieber, S.M. Paul, L. Amler, T. Riehl, E. Schleifman, C.A. Cummings, P.S. Hegde, W. Zou, A. Sandler, M. Ballinger, D.S. Shames
Journal: Annals of Oncology (2017)
Heparin-functionalized polymer graft surface eluting MK2 inhibitory peptide to improve hemocompatibility and anti-neointimal activity
Authors: Yunki Lee, Phuong Le Thi, Gyeung Mi Seon, Seung Bae Ryu, Colleen M. Brophy, YongTae Kim, Jong-Chul Park, Ki Dong Park, Joyce Cheung-Flynn, Hak-Joon Sung
Journal: Journal of Controlled Release (2017)
How useful is PET/CT in the evaluation of fever/inflammation of unknown origin? Comment on the article by Schönau <i>et al</i>
Authors: Markus Bredemeier
Journal: Annals of the Rheumatic Diseases (2017)

We read with interest the article by Schonau et al ,1 a rare prospective study performed in the setting of fever/inflammation of unknown origin (FUO/IUO). They concluded that positron emitted tomography (PET)/CT is helpful in the diagnosis of the underlying cause of fever/inflammation not elucidated with a preliminary diagnostic work-up. Notwithstanding the merits of the study, there are aspects that may deserve additional comments.

To fulfil the concept of FUO/IUO, the patient has to have a condition whose diagnosis is …
Torture victims were unlawfully detained despite doctors’ concerns
Authors: Clare Dyer
Journal: BMJ (2017)

The UK government acted unlawfully in locking up too many torture victims in immigration detention centres, a High Court judge has ruled.1

Mr Justice Ouseley backed a legal challenge by seven detainees who were locked up during the asylum process, despite concerns among doctors that they had previously suffered torture. They were joined in bringing the claim by Medical Justice, a charity working for the health rights of detainees.

The seven were kept in detention centres in spite of rules approved by parliament stating that people who had …
Influence of an intronic polymorphism in the MITF gene, of melanogenic pathway, in the risk and the prognosis of cutaneous melanoma
Authors: C. Torricelli, C. Oliveira, B. Sá Carvalho, J.K. Silva, G.V.B. Gomez, W.D.L. Oliveira, J.A. Rinck-Junior, A.M. Moraes, M.M. Ortega, C.S.P. Lima, G.J. Lourenço
Journal: Annals of Oncology (2017)
Fortnightly review: Hormone replacement therapy
Authors: E. Barrett-Connor
Journal: BMJ (1998)

The number of women who will live half their adult lives after the menopause increases every year.1 A challenging question for doctors is how women should be counselled about postmenopausal oestrogen therapy.

#### Summary points

Five or more years of postmenopausal oestrogen is the standard of care for the prevention or treatment of osteoporosis; benefit requires continued use

Oestrogen increases the risk of endometrial cancer during and after use,unless it is taken with adequate progestogen

It probably increases the risk of breast cancer, but only during current use

It may reduce the risk of coronary heart disease

Routine oestrogen treatment should not be recommended until more risk:benefit data are available from clinical trials

This review is based on observations during 25 years of research into women's health, and on Medline searches on oestrogen or menopause. Only recent publications are cited. Unless otherwise stated, oestrogen therapy refers to treatment of postmenopausal women with pharmacological doses of oral oestrogen taken alone or with an oral progestogen.

About 75% of women in English speaking countries experience no troublesome symptoms during the menopause transition.2 Population studies have shown that symptoms are less common or different in other countries, and more common and more severe after an induced menopause. Hot flushes and night sweats are the only symptoms universally reported to respond (usually almost immediately) to oestrogen. Without treatment, hot flushes typically disappear within 1-2 years, but in some untreated women they continue for more than 20 years.

After the menopause the vaginal wall becomes thinner and less vascular, changes which may be accompanied by vaginal dryness and dyspareunia. Intravaginal oestrogen prevents and treats these symptoms and also reduces the risk of recurrent urinary tract infection, probably by modifying the vaginal flora.3 Urinary incontinence, which becomes more common with increasing age, is not usually improved …
Serial ductal lavage for biomarker assessment in a phase 2 prevention study with tamoxifen
Authors: S. Khan, H. A. Lankes, D. Patil, M. Bryk, R. Nayar, N. Hou, H. Krontiras, A. Rademaker
Journal: Journal of Clinical Oncology (2007)

1509 Background: Effective methods of epithelial sampling to measure breast-specific biomarkers will aid the rapid evaluation of new preventive interventions. We report a proof-of-principle Phase 2 study to assess the utility of ductal lavage (DL) to measure biomarkers using tamoxifen (TAM) as the gold standard prevention agent. Methods: We enrolled women with a 5-year Gail risk &gt;1.6 or the unaffected breast of women with breast cancer =1 cm. After entry DL, participants chose TAM or observation (OBS), and underwent repeat DL 6 months later. Samples were processed for cytology and immunohistochemistry for ER and Ki-67 labeling indices (LIs). If =1 duct showed atypia, the sample was called atypical. LI data were analyzed by duct (comparing the same duct at 2 time points) and by woman (comparing the mean of all ducts at 2 time points). Results: Of 168 women recruited, 135 (80%) underwent entry and repeat DL; 82 (49%) had sufficient cells for analysis at both time points (mean age 50 years, mean Gail 3.0). 44 chose observation and 38 chose TAM. Cytologic findings, by woman and by duct, showed significantly greater net improvement (from atypical to benign) in the TAM than in the OBS group (see table ). The repeat ER and Ki-67 LIs showed a significant reduction from entry within the TAM group (p=0.01 and 0.0001, respectively), but not in the OBS group when analysed by duct. Similarly, in analyses by woman, the ER and Ki-67 LIs decreased from entry to repeat DL within the TAM group (p=0.046 and 0.004 respectively), with minimal changes in the observation group. Between-group data are shown in the table and are similar to the within- group differences. Conclusions: Using DL, we saw the expected changes in TAM-related biomarkers, with stronger reductions in duct-to- duct comparisons than when findings were averaged across ducts in individual women. However, the 51% attrition rate of subjects from recruitment to biomarker analyses, along with the expense of DL, raises questions regarding the efficiency of this procedure in biomarker assessment over time. [Table: see text] No significant financial relationships to disclose.
Neuropsychiatric comorbidity among adolescents with psoriasis
Authors: E. Galili, A. Barzilai, R. Shreberk-Hassidim, I. Merdler, T. Caspi, N. Astman
Journal: British Journal of Dermatology (2017)

Summary Background Psoriasis is a known risk factor for neuropsychiatric diseases among adults. Less is known about the impact on adolescents. Objectives To investigate the association between psoriasis and neuropsychiatric comorbidity and social skills among adolescents. Methods A population-based cross-sectional study between 1 January 1999 and 1 January 2014 was conducted. The study included 1746 and 1366 adolescents (aged 16 to 18) with mild and moderate-to-severe psoriasis, respectively. The psoriasis patients were diagnosed by a dermatologist. Neuropsychiatric diseases were diagnosed by a neurologist and a psychiatrist, as appropriate. Social skills were evaluated using psychosocial assessment. Patients with psoriasis were compared with 884 653 healthy controls by a multivariate analysis adjusted for age, sex, country of origin, socioeconomic status, cognitive skills and body mass index. A subgroup evaluation was done for comorbidity that could only be evaluated for part of the recruitment years, using a univariate analysis. Results Overall chronic headaches (8·1% vs. 3·4%), intermediate frequency migraine (4·8% vs. 1·6%), low-frequency migraine and nonmigraine headaches (3·4% vs. 1·8%) were associated with moderate-to-severe psoriasis only compared with healthy controls [adjusted odds ratios (OR) 1·9, 95% confidence interval (CI) 1·6–2·4; 2·3, 95% CI 1·8–3·0 and 1·5, 95% CI 1·1–2·1, respectively]. Anxiety disorders (2·1% vs. 0·8%) and impaired social adjustment skills (7·5% vs. 4·2%) were also associated with moderate-to-severe psoriasis only compared with healthy controls [adjusted ORs 2·9, 95% CI 1·6–5·5 and 1·9, 95% CI 1·3–2·6 (of 466 vs. 265 023), respectively]. Conclusions Psoriasis among adolescents is associated with neuropsychiatric comorbidity and impaired adjustment skills, depending on disease severity.
Moderate Alcohol Consumption Is Associated With Lower Risk for Heart Failure But Not Atrial Fibrillation
Authors: Augusto Di Castelnuovo, Simona Costanzo, Marialaura Bonaccio, Livia Rago, Amalia De Curtis, Mariarosaria Persichillo, Francesca Bracone, Marco Olivieri, Chiara Cerletti, Maria Benedetta Donati, Giovanni de Gaetano, Licia Iacoviello, Licia Iacoviello, Maria Benedetta Donati, Giovanni de Gaetano, Jos Vermylen, Ignacio De Paula Carrasco, Simona Giampaoli, Antonio Spagnuolo, Deodato Assanelli, Vincenzo Centritto, Pasquale Spagnuolo, Dante Staniscia, Francesco Zito, Americo Bonanni, Chiara Cerletti, Amalia De Curtis, Augusto Di Castelnuovo, Licia Iacoviello, Roberto Lorenzet, Antonio Mascioli, Marco Olivieri, Domenico Rotilio, Augusto Di Castelnuovo, Marialaura Bonaccio, Simona Costanzo, Francesco Gianfagna, Marco Olivieri, Maurizio Giacci, Antonella Padulo, Dario Petraroia, Amalia De Curtis, Federico Marracino, Maria Spinelli, Christian Silvestri, Americo Bonanni, Marialaura Bonaccio, Francesca De Lucia, Francesco Gianfagna, Branislav Vohnout, Franco Zito, Mariarosaria Persichillo, Angelita Verna, Maura Di Lillo, Irene Di Stefano, Agostino Pannichella, Antonio Rinaldo Vizzarri, Branislav Vohnout, Agnieszka Pampuch, Antonella Arcari, Daniela Barbato, Francesca Bracone, Simona Costanzo, Carmine Di Giorgio, Sara Magnacca, Simona Panebianco, Antonello Chiovitti, Federico Marracino, Sergio Caccamo, Vanesa Caruso, Livia Rago, Daniela Cugino, Francesco Zito, Francesco Gianfagna, Alessandra Ferri, Concetta Castaldi, Marcella Mignogna, Tomasz Guszcz, Romina di Giuseppe, Paola Barisciano, Lorena Buonaccorsi, Floriana Centritto, Antonella Cutrone, Francesca De Lucia, Francesca Fanelli, Iolanda Santimone, Anna Sciarretta, Maura Di Lillo, Isabella Sorella, Irene Di Stefano, Emanuela Plescia, Alessandra Molinaro, Christiana Cavone, Giovanna Galuppo, Maura Di Lillo, Concetta Castaldi, Dolores D'Angelo, Rosanna Ramacciato, Simona Costanzo, Simona Costanzo, Marco Olivieri, Livia Rago, Simona Costanzo, Amalia de Curtis, Licia Iacoviello, Mariarosaria Persichillo
Journal: JACC Heart Failure (2017)
Consider Quality of Life to Improve Quality of Cancer Guidelines—Reply
Authors: Ryan P. Merkow, Deborah Korenstein, Shrujal S. Baxi
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Cardiovascular Effects of Renal Distal Tubule Deletion of the FGF Receptor 1 Gene
Authors: Xiaobin Han, Jed Ross, Ganesh Kolumam, Min Pi, Junichiro Sonoda, Gwendalyn King, L. Darryl Quarles
Journal: Journal of the American Society of Nephrology (2017)

The bone-derived hormone fibroblast growth factor–23 (FGF-23) activates complexes composed of FGF receptors (FGFRs), including FGFR1, and α -Klotho in the kidney distal tubule (DT), leading to increased sodium retention and hypertension. However, the role of FGFR1 in regulating renal processes linked to hypertension is unclear. Here, we investigated the effects of selective FGFR1 loss in the DT. Conditional knockout (cKO) of FGFR1 in the DT ( FGFR1DT-cKO mice) resulted in left ventricular hypertrophy (LVH) and decreased kidney expression of α -Klotho in association with enhanced BP, decreased expression of angiotensin converting enzyme 2, and increased expression of the Na + -K + -2Cl − cotransporter. Notably, recombinant FGF-23 administration similarly decreased the kidney expression of α -Klotho and induced LVH in mice. Pharmacologic activation of FGFR1 with a monoclonal anti-FGFR1 antibody (R1MAb1) normalized BP and significantly attenuated LVH in the Hyp mouse model of excess FGF-23, but did not induce a response in FGFR1DT-cKO mice. The hearts of FGFR1DT-cKO mice showed increased expression of the transient receptor potential cation channel, subfamily C, member 6 (TRPC6), consistent with cardiac effects of soluble Klotho deficiency. Moreover, administration of recombinant soluble Klotho lowered BP in the Hyp mice. Thus, FGFR1 in the DT regulates systemic hemodynamic responses opposite to those predicted by the actions of FGF-23. These cardiovascular effects appear to be mediated by paracrine FGF control of kidney FGFR1 and subsequent regulation of soluble Klotho and TRPC6. FGFR1 in the kidney may provide a new molecular target for treating hypertension.
Expression of long non-coding RNA MFI2-AS1 is a strong predictor of recurrence in sporadic localized clear-cell renal cell carcinoma
Authors: R. Flippot, R. Mouawad, J-P. Spano, M. Rouprêt, E. Compérat, M-O. Bitker, J. Parra, C. Vaessen, F. Allanic, Q. Manach, N. Tannir, D. Khayat, X. Su, G. Malouf
Journal: Annals of Oncology (2017)
Aumento da incidência da resistência da Salmonella typhimurium DT104 epidémica ao trimetoprim e ciprofloxacina em Inglaterra e País de Gales
Authors: E J Threlfall, L. R. Ward, B Rowe
Journal: Eurosurveillance (1997)

Desde 1990, as estirpes de Salmonella typhimurium do fagotipo (DT) 104 (=DT104) que possuem resistencia cromossomica a ampicilina, cloranfenicol, estreptomicina, sulfonamidas e tetraciclinas (=fenotipo ACSSuT) (1) tem-se tornado mais comuns no homem em Inglaterra e Gales (figura 1). Desde 1992, apenas a S. enteritidis do fagotipo 4 tem sido responsavel por mais casos de salmonelose humana (2). Em 1995, noventa e quatro por cento dos isolamentos enviados para o Laboratory of Enteric Pathogens (LEP) do Public Health Laboratory Service (PHLS) pelos laboratorios de Inglaterra e Gales eram multirresistente para quatro ou mais antimicrobianos
No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate-to-severe plaque psoriasis
Authors: B.E. Strober, R.G.B. Langley, A. Menter, M. Magid, B. Porter, T. Fox, J. Safi, C. Papavassilis
Journal: British Journal of Dermatology (2017)

Concerns have emerged over the potential for brodalumab, a monoclonal antibody that binds to the human interleukin (IL)-17 receptor A and blocks the activity of multiple IL-17 isoforms, to increase risk of suicidal ideation and behaviour. Although the validity of this association has been questioned,1,2 brodalumab has a boxed warning regarding suicidality in its US label and is only available through a Risk Evaluation and Mitigation Strategy. Regardless of the true association between suicidality and brodalumab, the demonstrated adverse impact of psoriasis on mental health necessitates careful assessment for possible psychiatric adverse effects of psoriasis therapies, including those that inhibit the IL-17 pathway.

This article is protected by copyright. All rights reserved.
GW28-e0066 Comparative assessment of “plaque/media” change on three modalities of IVUS immediately after implantation of either Everolimus-Eluting Bioresorbable Vascular Scaffold or Everolimus-Eluting Metallic Stent in Absorb II Study
Authors: Yaping Zeng, Patrick W. Serruys
Journal: Journal of the American College of Cardiology (2017)
Urine-derived lymphocytes (UDLs) as a non-invasive surrogate marker of tumour infiltrating lymphocytes (TILs) in patients with muscle invasive bladder cancer (MIBC)
Authors: Y.N.S. Wong, K. Joshi, P. Khetrapal, M. Ismail, J. Linares, A.U. Akarca, J.L. Reading, A. Furness, A. Feber, U. McGovern, C. Swanton, A. Freeman, T.P. Briggs, J. Kelly, T. Marafioti, K.S. Peggs, T. Powles, B.M. Chain, M. Linch, S. Quezada
Journal: Annals of Oncology (2017)
Pan-cancer genomic analysis of MSI-H tumors reveals commonly altered pathways
Authors: S.E. Trabucco, S.L. Maund, R. Hartmaier, K. Gowen, J. Sun, G.M. Frampton, P.J. Stephens, P.S. Hegde, S-M.A. Huang
Journal: Annals of Oncology (2017)
Clinical utilization and performance characteristics of large NGS gene panel in the community practice setting.
Authors: Stephen Lyle, Jia Xu, Claudia S. Huettner, Scott Schell, Meaghan Russell, Alexei Protopopov
Journal: Journal of Clinical Oncology (2015)

e17508 Background: Evaluation of patient tumors by large NGS gene panels is becoming routine at large academic cancer centers. However, adoption and utilization of these diagnostic tools has not been studied in the community oncology practice setting. Matching a patient’s tumor mutational profile with targeted agents is the primary goal of personalized medicine in all treatment settings. The number of therapies entering clinical trials is continually increasing and these trials are becoming widely available in community oncology practices. Unlike academic centers where institutional funds typically cover NGS testing, community setting testing is reimbursed by commercial and government payers. We evaluated clinical utilization, performance, and payer characteristics in 100 sequential large NGS panels ordered by community practice oncologists. Methods: 100 sequential NGS gene panel results, obtained from community practice oncology groups, were evaluated for tumor type, stage and specimen source. Tumor profiling of 413 genes (including translocations in ALK, RET, ROS) was performed in a CLIA-certified laboratory (KEW Group Inc, Cambridge, MA), and variants were sorted into three major categories (FDA-approved therapy; Therapy in clinical development; and other variants in cancer genes). Insurance payer information was reviewed. Results: 100 sequential NGS gene panel results, obtained from community practice oncology groups, were evaluated for tumor type, stage and specimen source. Tumor profiling of 413 genes (including translocations in ALK, RET, ROS) was performed in a CLIA-certified laboratory (KEW Group Inc, Cambridge, MA), and variants were sorted into three major categories (FDA-approved therapy; Therapy in clinical development; and other variants in cancer genes). Insurance payer information was reviewed. Conclusions: The majority ofNGS panels utilized in the community practice setting represent small biopsies of lung, colon and melanoma patients where genomic testing’s value and performance is readily apparent. Private payer reimbursement provides access for testing.